MCT Study
tumor, triple-negative breast cancer, death, breast cancer
TUMOR, TRIPLE-NEGATIVE BREAST CANCER, DNA DAMAGE, BREAST CANCER
The MCT study was performed at OncoDesign. All experimental procedures were approved by the Ethics Committee of OncoDesign (C2EA; registration number 91) and were performed in full compliance with the ARRIVE guidelines, EU Directive 2010/63/ EU for animal experiments, and the 2013 French Regulatory Decree. All efforts were made to minimize animal suffering and to reduce the number of animals used (The MCT dataset was composed of 25 PDX breast cancer models provided by the IMODI French consortium (HR for hormonal receptor subgroup (ER and/or PRTNBC for triple-negative breast cancer subgroup (ERThe 63-day follow-up included an on-treatment period (with three administrations 7 days apart) and then no treatment from day 14 onward. For each mouse, tumor size was measured using calipers approximately every 3 days during follow-up.Liposomal irinotecan is a chemotherapy drug (cytotoxic agent) whose active ingredient is irinotecan (a topoisomerase I inhibitor) encapsulated in a liposome. Irinotecan and its active metabolite SN-38 inhibits topoisomerase I, a crucial enzyme in DNA replication. As a result, religation of DNA single-strand breaks is prevented, leading to exposure time-dependent, double-stranded DNA damage and cell death (